Orchid Pharma OFS subscribed 2.5x; India Pesticides IPO 3.8x on Day 2

Shares of Orchid Pharma hit 10 per cent lower limit to end at Rs 1,188 on Thursday

BSE
Power plant equipment maker Bharat Heavy Electricals has more than doubled this year, making it among the top gainers in Bloomberg Intelligence’s basket. (Photo: Bloomberg)
BS Reporter Mumbai
2 min read Last Updated : Jun 25 2021 | 12:00 AM IST
The share sale by promoters of Orchid Pharma saw 2.5 times more demand than shares on offer. The 3.28 million share offering garnered bids for 8.32 million shares from institutional investors. Most of the bids came in at Rs 432, data provided by BSE showed. The floor price for the share sale was set Rs 375. At a discount of more than 70 per cent to the stock’s previous day’s close of Rs 1,320.

Shares of Orchid Pharma hit 10 per cent lower limit to end at Rs 1,188 on Thursday. Promoter Dhanuka Laboratories’ holding in the company is currently at 98 per cent. Dhanuka had taken over the company through corporate insolvency resolution process. Shares of the company have zoomed more than 60 times in the past one year. Market experts said low free float led to distortion in the stock price. Following the OFS, the promoter stake in the company will drop by 8 per cent.

India Pesticides IPO subscribed 3.8 times on day 2

The IPO of India Pesticides, a manufacturer of agro-chemicals, has garnered 3.8 times subscription on Thursday, a day before its close. Bulk of the demand so far has come from retail investors. The price band for the issue is Rs 290 –Rs 296 per share. At the top-end, the company will have a post-listing market cap of Rs 3,409 crore. The IPO comprises Rs 100 crore in fresh fund raise and the remaining is secondary share sale.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Orchid PharmaStock movemnet

Next Story